Abstract
Diabetics are regarded a special category of patients known to experience higher rates of cardiovascular complications as compared to the non-diabetic ones. Despite substantial efforts to minimize these risks, with aggressive antiplatelet and lipid lowering therapy, some of the diabetic patients still have a considerable residual risk for cardiovascular adverse events. Important preclinical data with potent lipid-lowering agents, like fibrates, omega-3-fatty acids, and niacin, have shown that they can provide sufficient help in reducing rates of cardiovascular events. In the present review, we are aim to explain their basic mechanisms of action, to present all the available clinical data regarding the efficacy of those agents, and to identify specific diabetic patients’ subsets, in whom supplementary therapy with those agents could provide substantial benefit in terms of clinical outcome and not only lipid profile improvement.
Keywords: Fibrates, omega 3, fish oil, niacin, myocardial infarction, stroke, statins, diabetes.
Current Pharmaceutical Design
Title:Confronting the Residual Cardiovascular Risk Beyond Statins: The Role of Fibrates, Omega-3 Fatty Acids, or Niacin, in Diabetic Patients
Volume: 20 Issue: 22
Author(s): Georgios A. Christou, Evangelos C. Rizos, Aris Mpechlioulis, Carlo Penzo, Andrea Pacchioni and Dimitrios N. Nikas
Affiliation:
Keywords: Fibrates, omega 3, fish oil, niacin, myocardial infarction, stroke, statins, diabetes.
Abstract: Diabetics are regarded a special category of patients known to experience higher rates of cardiovascular complications as compared to the non-diabetic ones. Despite substantial efforts to minimize these risks, with aggressive antiplatelet and lipid lowering therapy, some of the diabetic patients still have a considerable residual risk for cardiovascular adverse events. Important preclinical data with potent lipid-lowering agents, like fibrates, omega-3-fatty acids, and niacin, have shown that they can provide sufficient help in reducing rates of cardiovascular events. In the present review, we are aim to explain their basic mechanisms of action, to present all the available clinical data regarding the efficacy of those agents, and to identify specific diabetic patients’ subsets, in whom supplementary therapy with those agents could provide substantial benefit in terms of clinical outcome and not only lipid profile improvement.
Export Options
About this article
Cite this article as:
Christou A. Georgios, Rizos C. Evangelos, Mpechlioulis Aris, Penzo Carlo, Pacchioni Andrea and Nikas N. Dimitrios, Confronting the Residual Cardiovascular Risk Beyond Statins: The Role of Fibrates, Omega-3 Fatty Acids, or Niacin, in Diabetic Patients, Current Pharmaceutical Design 2014; 20 (22) . https://dx.doi.org/10.2174/13816128113196660674
DOI https://dx.doi.org/10.2174/13816128113196660674 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Characterization of Neuroprotective Peptide, Humanin
Current Medicinal Chemistry Pharmacogenomic Considerations of the Insertion / Deletion Gene Polymorphism of the Angiotensin I-Converting Enzyme and Coronary Artery Disease
Current Vascular Pharmacology Xanthine Oxidase Perspective in Human Health
Current Biotechnology Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design Variability in the Effects of Nicotine on Different Regions of the Brain: Changes in the Concentration of Superoxide Dismutase Isoforms
Central Nervous System Agents in Medicinal Chemistry Inhibitors of Angiogenesis in Cancer Therapy – Synthesis and Biological Activity
Current Medicinal Chemistry Flavonoids and Dementia: An Update
Current Medicinal Chemistry Oxidative Stress: Apoptosis in Neuronal Injury
Current Alzheimer Research Polyphenols, Antioxidants and the Sympathetic Nervous System
Current Pharmaceutical Design Cross-Reactive Reactions to Nonsteroidal Anti-Inflammatory Drugs
Current Pharmaceutical Design Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Synthesis and Antimicrobial Activity of Nitroalkenyl Arenes
Anti-Infective Agents In Vivo MRI in Different Models of Experimental Epilepsy
Current Drug Targets Polyamines in Gut Inflammation and Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Shortened Process Chain for the Production of Micro Parts by 2- Component-Micro Injection Moulding
Micro and Nanosystems Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the PROTECT Project
Current Clinical Pharmacology AT1 Receptor Antagonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Integrated Quality by Design (QbD) Approach for Stability Indicating RPHPLC Method for the Estimation of Tadalafil Hydrochloride in Bulk Drug and Pharmaceutical Formulations
Current Pharmaceutical Analysis Biomarkers Determining Prognosis of Atrial Fibrillation Ablation
Current Medicinal Chemistry